Tag: conjugate vaccine market report

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

#How Much Will The Conjugate Vaccine Market Be Worth By 2029?#_x000D_

In recent times, the conjugate vaccine market has seen substantial growth. It is projected to expand from $18.9 billion in 2024 to $21.26 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 12.5%. Historical growth can be traced back to factors such as disease prevalence, government vaccination initiatives, heightened awareness, focus on paediatric vaccinations, and trends in preventive healthcare._x000D_

_x000D_

Looking into the future, the conjugate vaccine market is set to experience substantial growth and is projected to reach $33.99 billion by 2029, growing at a compound annual growth rate (CAGR) of 12.4%. Driving factors for this anticipated addendum in the forecast period include the broadening of vaccination policies, growing old-age demographics, emerging vaccine indications, issues of global health security, international alliances, and the effect of economic progress. The period’s primary trends encompass collaborations and alliances for vaccine distribution, customization for populations at greater risk, application amid rising infectious diseases, progress in vaccine production technologies, and global health endeavors for vaccine equity._x000D_

_x000D_

#Get A Free Sample Of The Report:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=10850&type=smp_x000D_

_x000D_

#What Are The Primary Factors Supporting The Conjugate Vaccine Market Expansion?#_x000D_

The escalation in the utilization of conjugate vaccines among adults is anticipated to boost the conjugate vaccine market’s growth. Conjugate vaccines, which are formulated to incite a potent immune response to bacterial capsular polysaccharides, reinforce the body’s bacterial infection defense mechanism. Applying conjugate vaccines to adults lessens the chances of severe sickness and complications and prevents the transmission of these bacterial ailments by provoking a sturdy immune reaction. For example, as per the UK Health Security Agency (UKHSA) reports in June 2024, the ‘6-in-1’ vaccine in the UK retained a steady 91.7% coverage over 12 months. Consistent too was the first pneumococcal conjugate vaccine (PCV) dose at 93.7%. The Rotavirus coverage reported a 0.6% growth, reaching 89.3%, while the second dose of the meningitis B vaccine (MenB2) saw a slight increment of 0.1%, moving up to 91.5%. Thus, the escalating conjugate vaccine usage among adults is fueling the conjugate vaccine market’s expansion._x000D_

_x000D_

#How Is The Global Conjugate Vaccine Market Broken Down By Segment?#_x000D_

The conjugate vaccine market covered in this report is segmented – _x000D_

_x000D_

1) By Product Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine_x000D_

2) By Pathogen: Bacterial, Viral_x000D_

3) By Disease Indication: Pneumococcal, Influenza, Meningococcal, Typhoid_x000D_

4) By Patient: Pediatric, Adults_x000D_

5) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Monovalent Conjugate Vaccines: Single Pathogen Conjugate Vaccines_x000D_

2) By Multivalent Conjugate Vaccines: Multiple Pathogen Conjugate Vaccines, Combination Conjugate Vaccines_x000D_

_x000D_

#Which Trends Are Likely To Redefine Growth Paths In The Conjugate Vaccine Market?#_x000D_

The emergence of innovations in conjugate vaccines is a trending phenomenon being observed in the conjugate vaccine market. The companies in this market are striving to create innovative conjugate vaccines to maintain their market position. For example, in June 2022, Pfizer Inc., an American pharmaceutical and biotechnology firm, unveiled Prevnar 20, a pneumococcal 20-valent conjugate vaccine, in Canada. This vaccine is designed to safeguard adults aged 18 or older from pneumonia and serious pneumococcal infections. Prevnar 20 features conjugates for the 13 serotypes already included in PREVNAR 13, along with conjugates for seven other serotypes linked to severe pneumococcal diseases, high mortality rates, antibiotic resistance, and meningitis._x000D_

_x000D_

#Which Firms Are Making The Biggest Impact In The Conjugate Vaccine Market?#_x000D_

Major companies operating in the conjugate vaccine market include Sanofi S.A., Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute of India Private Limited, Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., Bio-Med Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Panacea Biotec Ltd., Protein Sciences Corporation, Seqirus _x000D_

_x000D_

#Access The Complete Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report_x000D_

_x000D_

#Which Geographic Regions Are Creating Strong Demand In The Conjugate Vaccine Market?#_x000D_

North America was the largest region in the global conjugate vaccine market in 2024. The regions covered in the conjugate vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa_x000D_

_x000D_

#Customize Your Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=10850&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Large Is the Conjugate Vaccine Market Expected to Be in 2029?

In the past few years, there has been a swift expansion in the size of the conjugate vaccine market. The market is poised to escalate from $18.9 billion in 2024 to $21.26 billion in 2025, reflecting a compound annual growth rate (CAGR) of 12.5%. Factors fueling the growth during the historical period include the burden of diseases, implementation of government immunization programs, heightened awareness, a focus on pediatric vaccination, and preventive healthcare trends.

Over the coming years, the conjugate vaccine market is anticipated to witness swift expansion. The market size is projected to soar to “$33.99 billion in 2029”, boasting a compound annual growth rate (CAGR) of “12.4%”. The surge during this forecasted period can be credited to factors such as broadening immunization policies, an aging demographic, introduction of new vaccine indications, international health security issues, global cooperation, and the effects of economic development. The period also unveils major trends like collaborations and partnerships for distributing vaccines, tailored strategies for high-risk groups, applications in the field of emerging infectious diseases, technological advancements in vaccine production, along with worldwide health initiatives advocating for vaccine equality.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10850&type=smp

What Are The Contributors To Demand In The Conjugate Vaccine Market?

The conjugate vaccine market is predicted to grow due to the rising use of these vaccines among adults. Conjugate vaccines play a crucial role in provoking a powerful immune response against bacterial capsular polysaccharides, thus enhancing the body’s capacity to ward off bacterial infections. The incorporation of conjugate vaccines into adult immunization schedules helps minimize the risk of severe disease, complications, and transmission of bacterial illnesses by eliciting a strong immune response. For instance, a report from the UK Health Security Agency (UKHSA) in June 2024, indicated that the ‘6-in-1’ vaccine in the UK had a consistent 12-month coverage of 91.7%. The pneumococcal conjugate vaccine (PCV) sustained an uptake of 93.7%. The cover for the Rotavirus saw a rise of 0.6%, touching 89.3%, while the second dose of the meningitis B vaccine (MenB2) increased by 0.1%, reaching 91.5%. These trends indicate that the escalating use of conjugate vaccines for adults is fueling the growth of the conjugate vaccine market.

What Segmentation Categories Are Included In The Conjugate Vaccine Market Analysis?

The conjugate vaccine market covered in this report is segmented –

1) By Product Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine

2) By Pathogen: Bacterial, Viral

3) By Disease Indication: Pneumococcal, Influenza, Meningococcal, Typhoid

4) By Patient: Pediatric, Adults

5) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users

Subsegments:

1) By Monovalent Conjugate Vaccines: Single Pathogen Conjugate Vaccines

2) By Multivalent Conjugate Vaccines: Multiple Pathogen Conjugate Vaccines, Combination Conjugate Vaccines

What Long-Term Trends Are Likely To Affect The Conjugate Vaccine Market?

The growing trend of innovation in the field of conjugate vaccines is witnessing significant traction in the conjugate vaccine market. Market players in the conjugate vaccine space are diligently developing novel conjugate vaccines to secure their market position. As an illustration, Pfizer Inc., a biotechnology and pharmaceutical company headquartered in the US, released Prevnar 20, a pneumococcal 20-valent conjugate vaccine in Canada in June 2022. Aimed at preventing pneumonia and formidable pneumococcal infections in adults aged 18 years and up, Prevnar 20 incorporates conjugates for an extra seven serotypes linked to invasive pneumococcal disease, elevated fatality rates in cases, resistance to antibiotics, and meningitis, in addition to the 13 serotypes already covered by PREVNAR 13.

Who Are The Top-Ranked Companies In The Conjugate Vaccine Market Today?

Major companies operating in the conjugate vaccine market include Sanofi S.A., Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute of India Private Limited, Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., Bio-Med Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Panacea Biotec Ltd., Protein Sciences Corporation, Seqirus

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report

How Is Conjugate Vaccine Market Adoption Varying Across Different Regions And Sectors?

North America was the largest region in the global conjugate vaccine market in 2024. The regions covered in the conjugate vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10850&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Conjugate Vaccine Market Grown from 2024 to 2025?

In recent times, there has been a sharp increase in the size of the conjugate vaccine market. This market is projected to expand from a value of $18.9 billion in 2024 to a worth of $21.46 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 13.5%. This growth during the historic period can be credited to several factors including the prevalence of disease, government-run immunization initiatives, heightened awareness, a focus on pediatric vaccination, and emerging trends in preventive healthcare.

What Growth Rate Is Anticipated for the Conjugate Vaccine Market in the Coming Years?

In the coming years, the conjugate vaccine market is projected to experience significant expansion, reaching a valuation of “$34.59 billion in 2029 and registering a compound annual growth rate (CAGR) of 12.7%. Factors contributing to this growth during the forecast period include broader immunization policies, changes in population ages, new indications for vaccines, global health and safety issues, international cooperation, and the influence of economic development. Key trends during the forecast period encompass joint efforts for vaccine distribution, strategic approaches for populations at high-risk, utilization in upcoming infectious diseases, advances in vaccine production technologies, and worldwide health initiatives for equal vaccine distribution.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10850&type=smp

Who Are the Leading Companies in the Conjugate Vaccine Market?

Major companies operating in the conjugate vaccine market include Sanofi S.A., Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute of India Private Limited, Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., Bio-Med Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Panacea Biotec Ltd., Protein Sciences Corporation, Seqirus

What Are the Key Drivers of the Conjugate Vaccine Market?

The growth of the conjugate vaccine market is anticipated to be driven by the rising usage of these vaccines among adults. Conjugate vaccines, designed to generate a potent immune response against bacterial capsular polysaccharides, boost the human body’s protective barrier against bacterial infections. They help lower the chances of severe illness, complications, and the spread of these bacterial diseases by instigating a formidable immune response in adults. For example, a report by the UK Health Security Agency (UKHSA), a public health agency based in the UK, in June 2024 confirmed that the 12-month coverage of the ‘6-in-1’ vaccine in the UK remained stable at 91.7%. The initial dose of the pneumococcal conjugate vaccine (PCV) persisted at 93.7%. The coverage of the Rotavirus saw a rise of 0.6%, reaching 89.3%, and the second dose of the meningitis B vaccine (MenB2) saw a small increase of 0.1%, hitting 91.5%. As such, the higher uptake of conjugate vaccines among adults is fueling the expansion of the conjugate vaccine market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10850&type=smp

What Are the Key Market Segments in the Conjugate Vaccine Industry?

The conjugate vaccine market covered in this report is segmented –

1) By Product Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine

2) By Pathogen: Bacterial, Viral

3) By Disease Indication: Pneumococcal, Influenza, Meningococcal, Typhoid

4) By Patient: Pediatric, Adults

5) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users

Subsegments:

1) By Monovalent Conjugate Vaccines: Single Pathogen Conjugate Vaccines

2) By Multivalent Conjugate Vaccines: Multiple Pathogen Conjugate Vaccines, Combination Conjugate Vaccines

What Are the Latest Trends in the Conjugate Vaccine Market?

The development of novel conjugate vaccines is becoming a prominent trend in the conjugate vaccine market. Firms in this market are focusing their efforts on creating groundbreaking conjugate vaccines to maintain market dominance. For example, Pfizer Inc., an American pharmaceutical and biotech company, launched Prevnar 20 in Canada in June 2022. Prevnar 20 is a pneumococcal 20-valent conjugate vaccine designed to protect adults 18 years and older from pneumonia and invasive pneumococcal diseases. In addition to the 13 serotypes already included in PREVNAR 13, Prevnar 20 contains conjugates for seven more serotypes, known for their connection with invasive pneumococcal disease, high case-fatality rates, antibiotic resistance, and meningitis.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report

What Are the Key Regional Markets in the Conjugate Vaccine Industry?

North America was the largest region in the global conjugate vaccine market in 2024. The regions covered in the conjugate vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10850

This Report Delivers Insight On:

1. How big is the conjugate vaccine market, and how is it changing globally?

2. Who are the major companies in the conjugate vaccine market, and how are they performing?

3. What are the key opportunities and risks in the conjugate vaccine market right now?

4. Which products or customer segments are growing the most in the conjugate vaccine market?

5. What factors are helping or slowing down the growth of the conjugate vaccine market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the conjugate vaccine industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Has the Conjugate Vaccine Market Growth Performance Trended Historically, And What Lies Ahead?

In recent times, there has been a swift expansion in the conjugate vaccine market size. It is projected to escalate from $18.9 billion in 2024 to $21.46 billion in 2025, with a compound annual growth rate (CAGR) of 13.5%. Factors contributing to growth in this historical duration include disease prevalence, government-led vaccination initiatives, growing awareness, focus on child immunizations, and patterns in preventive healthcare.

The market for conjugate vaccines is projected to experience a swift increase in size in the coming years, with an expected valuation of $34.59 billion in 2029 and a compound annual growth rate (CAGR) of 12.7%. The anticipated rise during the forecast period can be credited to factors such as broader immunization policies, changes in the demographic profile due to aging, introduction of new vaccine indications, concerns regarding global health security, international cooperation, and the influence of economic development. The forecast period will witness significant trends such as collaborative efforts for distributing vaccines, custom strategies aimed at populations at higher risk, use in tackling emerging infectious diseases, advancements in the technology used for manufacturing vaccines, and worldwide health campaigns advocating for vaccine equity.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10850&type=smp

What are the Fundamental Drivers and Innovations Shaping the Conjugate Vaccine Market?

The conjugate vaccine market is predicted to thrive due to the rising utilization of conjugate vaccines among adults. These vaccines are engineered to generate a potent immune response against bacterial capsular polysaccharides, fortifying the human body’s resistance to bacterial diseases. Administering conjugate vaccines in adults lessens the threat of severe disease, complications, and the spread of these bacterial illnesses by prompting a powerful immune response. For instance, a report issued by the UK Health Security Agency (UKHSA) in June 2024 indicated that the 12-month coverage for the ‘6-in-1’ vaccine in the UK remained constant at 91.7%. The first dose of the pneumococcal conjugate vaccine (PCV) held stable at 93.7%. The Rotavirus vaccine coverage saw an increase of 0.6%, amounting to 89.3%. Concurrently, the second dose of the meningitis B vaccine (MenB2) inched up by 0.1% to 91.5%. Thus, the escalating use of conjugate vaccines for adults underpins the growth of the conjugate vaccine market.

How Is the Conjugate Vaccine Market Segmented?

The conjugate vaccine market covered in this report is segmented –

1) By Product Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine

2) By Pathogen: Bacterial, Viral

3) By Disease Indication: Pneumococcal, Influenza, Meningococcal, Typhoid

4) By Patient: Pediatric, Adults

5) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users

Subsegments:

1) By Monovalent Conjugate Vaccines: Single Pathogen Conjugate Vaccines

2) By Multivalent Conjugate Vaccines: Multiple Pathogen Conjugate Vaccines, Combination Conjugate Vaccines

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=10850&type=smp

Which Regions Are Driving the Next Phase of the Conjugate Vaccine Market Growth?

North America was the largest region in the global conjugate vaccine market in 2024. The regions covered in the conjugate vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Key Trends Are Shaping the Future of the Conjugate Vaccine Market?

The emergence of innovative conjugate vaccines is trending in the conjugate vaccine market. Firms in this industry are concentrating their efforts on introducing novel conjugate vaccines to maintain their market ranking. For instance, Pfizer Inc., an American pharmaceutical and biotech company, debuted Prevnar 20, a pneumococcal 20-valent conjugate vaccine, in Canada in June 2022. This launch aims to combat pneumonia and invasive pneumococcal infections in adults over the age of 18. Prevnar 20 consists of conjugates covering the 13 serotypes featured in PREVNAR 13 and also includes conjugates for an additional seven serotypes, which are linked to invasive pneumococcal disease, high mortality rate, antibiotic resistance, and meningitis.

View the full report here:

https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report

How Is the Conjugate Vaccine Market Defined and What Are Its Core Parameters?

Conjugate vaccines, also known as immunogen conjugates, are advanced immune system modulators widely employed to develop protection against invading pathogens or make particular antibodies against the target molecule. The conjugation process enhances the immune response and allows for a more effective immune system recognition of the pathogen.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10850

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the conjugate vaccine market grown in recent years?

The market size of conjugate vaccines has seen significant expansion in the past few years. Analysts predict an increase from $18.9 billion in 2024 to $21.46 billion in 2025, indicating a compound annual growth rate (CAGR) of 13.5%. Factors that have driven growth during the historic period include the burden of disease, governmental vaccination initiatives, heightened awareness of the issue, a focus on vaccinations for children, and a trend towards preventive healthcare.

How is the conjugate vaccine market size expected to evolve during the forecast period?

In the coming years, the conjugate vaccine industry is predicted to witness a substantial expansion, culminating to an expected size of $34.59 billion by 2029, with a compound annual growth rate (CAGR) of 12.7%. Factors contributing to this predicted growth during the projected period include extensive immunization strategies, changes in the elderly population, introduction of new vaccine indications, concerns over global health safety, international co-operation, and the repercussion of economic development. Various trends set to dominate the anticipated period comprise collaborations and alliances for the distribution of vaccines, bespoke methods for more vulnerable demographics, use in controlling new infectious diseases, advancements in vaccine production technology, and worldwide health agendas aiming for equal vaccine distribution.

Get your conjugate vaccine market report here!

https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report

Which key drivers are propelling the conjugate vaccine market’s growth?

The conjugate vaccine market is set to see significant growth due to the rising utilization of conjugate vaccines in adults. Designed to elicit potent immune reactions against bacterial capsular polysaccharides, conjugate vaccines bolster the body’s defensive capabilities against bacterial infections. Injecting adults with conjugate vaccines mitigates the potential for severe disease, complications, and the spread of bacterial illnesses by promoting a strong immune reaction. For instance, data from the UK Health Security Agency (UKHSA) in June 2024 indicated that the ‘6-in-1’ vaccine coverage in the UK remained steady at 91.7% over 12 months. The primary dose of the pneumococcal conjugate vaccine (PCV) held steady at 93.7%. The coverage for the rotavirus vaccine experienced a 0.6% increase, hitting 89.3%, while the second dose of the meningitis B vaccine (MenB2) saw an increase of 0.1%, achieving 91.5%. Hence, the expanded application of conjugate vaccines amongst adults is steering the expansion of the conjugate vaccine market.

What are the market segments in the conjugate vaccine industry?

The conjugate vaccine market covered in this report is segmented –

1) By Product Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine

2) By Pathogen: Bacterial, Viral

3) By Disease Indication: Pneumococcal, Influenza, Meningococcal, Typhoid

4) By Patient: Pediatric, Adults

5) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users

Subsegments:

1) By Monovalent Conjugate Vaccines: Single Pathogen Conjugate Vaccines

2) By Multivalent Conjugate Vaccines: Multiple Pathogen Conjugate Vaccines, Combination Conjugate Vaccines

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10850&type=smp

Which leading companies are shaping the growth of the conjugate vaccine market?

Major companies operating in the conjugate vaccine market include Sanofi S.A., Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute of India Private Limited, Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., Bio-Med Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Panacea Biotec Ltd., Protein Sciences Corporation, Seqirus

What key trends are currently impacting the conjugate vaccine market’s development?

The trend of innovation within the sphere of conjugate vaccines is becoming increasingly prevalent in the conjugate vaccine market. Companies that are active in this field are channeling their efforts in inventing novel conjugate vaccines in an attempt to maintain their footing in the market. Pfizer Inc., an American pharma and biotech firm, for example, introduced Prevnar 20, a pneumococcal 20-valent conjugate vaccine that targets pneumonia and invasive pneumococcal infections in adults of 18 years and older, in Canada in June 2022. Prevnar 20 consists of conjugates for the existing 13 serotypes covered by PREVNAR 13, along with additional conjugates for seven other serotypes linked to invasive pneumococcal disease, severe case-fatality rates, antibiotic resistance, and meningitis.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10850

Which geographic areas are influencing the growth of the conjugate vaccine market?

North America was the largest region in the global conjugate vaccine market in 2024. The regions covered in the conjugate vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Cancer Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

Dog Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/dog-vaccines-global-market-report

Veterinary Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/veterinary-vaccines-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Forecasted Expansion Rate of the Conjugate Vaccine Market Over the 2025–2034 Period?

There has been a significant expansion in the conjugate vaccine market in recent years. Its market value will surge from $18.9 billion in 2024 to reach $21.46 billion in 2025, experiencing a compound annual growth rate (CAGR) of 13.5%. The amplification in the historic period can be accredited to factors such as disease prevalence, government-led immunization programs, heightened awareness, focus on pediatric vaccination, and trends towards preventive healthcare.

In the coming years, a swift expansion is anticipated in the conjugate vaccine market size. It is predicted to escalate to “$34.59 billion by 2029, with a compound annual growth rate (CAGR) of 12.7%. Such progress during the forecast period can be linked to the enlargement of immunization protocols, the changing age population pattern, the emergence of new vaccine indications, concerns on worldwide health security, international collaboration, and the impact of economic development. Key trends to watch during the projection period include alliances and partnerships for the dissemination of vaccines, custom strategies for populations at high risk, application to newly emerging infectious diseases, advancements in vaccine production technologies, and worldwide health drives for equal distribution of vaccines.

Which Primary Drivers Are Supporting the Continued Expansion of the conjugate vaccine Market?

An uptick in the application of conjugate vaccines among adults is projected to accelerate the expansion of the conjugate vaccine market. These vaccines are engineered to elicit a potent immune reaction to bacterial capsular polysaccharides, bolstering the human body’s protective system against bacterial ailments. By stimulating a powerful immune response, adult usage of conjugate vaccines decreases the potential for severe sickness, further complications, and disease transmission. For example, in June 2024, information published by the UK Health Security Agency, a public health institution based in the UK, demonstrated that the coverage for the ‘6-in-1’ vaccine in the UK remained constant at 91.7%. The pneumococcal conjugate vaccine had a rate of 93.7% for the primary dose. Rotavirus coverage ticked up by 0.6% to hit 89.3%, while the second dosage of the meningitis B vaccine rose modestly by 0.1% to register 91.5%. Consequently, the elevated application of conjugate vaccines among adults is pushing ahead the rise of the conjugate vaccine market.

Explore Comprehensive Insights Into The Global Conjugate Vaccine Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10850&type=smp

Who Are the Leading Organizations Fueling the Expansion of the Conjugate Vaccine Market?

Major companies operating in the conjugate vaccine market include:

• Sanofi S.A._x000D_

• Pfizer Inc._x000D_

• Merck & Co. Inc._x000D_

• GlaxoSmithKline plc_x000D_

• Bharat Biotech International Limited_x000D_

Which Cutting-Edge Trends Are Expected to Drive the Conjugate Vaccine Market’s Growth?

The surge of innovation within the conjugate vaccine market is a major trend currently gaining traction. Corporations within this sphere are heavily invested in the research and development of novel conjugate vaccines to secure their competitive edge. For instance, US giant pharmaceutical and biotechnology corporation Pfizer Inc. introduced their latest product, Prevnar 20, in Canada in June 2022. This pneumococcal 20-valent conjugate vaccine is designed to combat pneumonia and invasive pneumococcal infections in adults 18 years and over. Remarkably, Prevnar 20 amalgamates the conjugates of the 13 serotypes that are already included under PREVNAR 13 in addition to seven new serotypes linked with invasive pneumococcal disease, high case-fatality rates, antibiotic opposition, and meningitis.

Secure Your Global Conjugate Vaccine Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report

What Are the Key Components of the Conjugate Vaccine Market, and How Do Its Segments Perform?

The conjugate vaccine market covered in this report is segmented –

1) By Product Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine

2) By Pathogen: Bacterial, Viral

3) By Disease Indication: Pneumococcal, Influenza, Meningococcal, Typhoid

4) By Patient: Pediatric, Adults

5) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users

Subsegments:

1) By Monovalent Conjugate Vaccines: Single Pathogen Conjugate Vaccines

2) By Multivalent Conjugate Vaccines: Multiple Pathogen Conjugate Vaccines, Combination Conjugate Vaccines

Which Regions Are Most Influential in Expanding the Conjugate Vaccine Market?

North America was the largest region in the global conjugate vaccine market in 2024. The regions covered in the conjugate vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Does the Definition of the Conjugate Vaccine Market Include?

Conjugate vaccines, also known as immunogen conjugates, are advanced immune system modulators widely employed to develop protection against invading pathogens or make particular antibodies against the target molecule. The conjugation process enhances the immune response and allows for a more effective immune system recognition of the pathogen.

Browse Through More Similar Reports By The Business Research Company:

Cancer Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

Dog Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/dog-vaccines-global-market-report

Veterinary Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/veterinary-vaccines-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Forecasted Expansion Rate of the Conjugate Vaccine Market Over the 2025–2034 Period?

There has been a significant expansion in the conjugate vaccine market in recent years. Its market value will surge from $18.9 billion in 2024 to reach $21.46 billion in 2025, experiencing a compound annual growth rate (CAGR) of 13.5%. The amplification in the historic period can be accredited to factors such as disease prevalence, government-led immunization programs, heightened awareness, focus on pediatric vaccination, and trends towards preventive healthcare.

In the coming years, a swift expansion is anticipated in the conjugate vaccine market size. It is predicted to escalate to “$34.59 billion by 2029, with a compound annual growth rate (CAGR) of 12.7%. Such progress during the forecast period can be linked to the enlargement of immunization protocols, the changing age population pattern, the emergence of new vaccine indications, concerns on worldwide health security, international collaboration, and the impact of economic development. Key trends to watch during the projection period include alliances and partnerships for the dissemination of vaccines, custom strategies for populations at high risk, application to newly emerging infectious diseases, advancements in vaccine production technologies, and worldwide health drives for equal distribution of vaccines.

Which Primary Drivers Are Supporting the Continued Expansion of the conjugate vaccine Market?

An uptick in the application of conjugate vaccines among adults is projected to accelerate the expansion of the conjugate vaccine market. These vaccines are engineered to elicit a potent immune reaction to bacterial capsular polysaccharides, bolstering the human body’s protective system against bacterial ailments. By stimulating a powerful immune response, adult usage of conjugate vaccines decreases the potential for severe sickness, further complications, and disease transmission. For example, in June 2024, information published by the UK Health Security Agency, a public health institution based in the UK, demonstrated that the coverage for the ‘6-in-1’ vaccine in the UK remained constant at 91.7%. The pneumococcal conjugate vaccine had a rate of 93.7% for the primary dose. Rotavirus coverage ticked up by 0.6% to hit 89.3%, while the second dosage of the meningitis B vaccine rose modestly by 0.1% to register 91.5%. Consequently, the elevated application of conjugate vaccines among adults is pushing ahead the rise of the conjugate vaccine market.

Explore Comprehensive Insights Into The Global Conjugate Vaccine Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10850&type=smp

Who Are the Leading Organizations Fueling the Expansion of the Conjugate Vaccine Market?

Major companies operating in the conjugate vaccine market include:

• Sanofi S.A._x000D_

• Pfizer Inc._x000D_

• Merck & Co. Inc._x000D_

• GlaxoSmithKline plc_x000D_

• Bharat Biotech International Limited_x000D_

Which Cutting-Edge Trends Are Expected to Drive the Conjugate Vaccine Market’s Growth?

The surge of innovation within the conjugate vaccine market is a major trend currently gaining traction. Corporations within this sphere are heavily invested in the research and development of novel conjugate vaccines to secure their competitive edge. For instance, US giant pharmaceutical and biotechnology corporation Pfizer Inc. introduced their latest product, Prevnar 20, in Canada in June 2022. This pneumococcal 20-valent conjugate vaccine is designed to combat pneumonia and invasive pneumococcal infections in adults 18 years and over. Remarkably, Prevnar 20 amalgamates the conjugates of the 13 serotypes that are already included under PREVNAR 13 in addition to seven new serotypes linked with invasive pneumococcal disease, high case-fatality rates, antibiotic opposition, and meningitis.

Secure Your Global Conjugate Vaccine Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report

What Are the Key Components of the Conjugate Vaccine Market, and How Do Its Segments Perform?

The conjugate vaccine market covered in this report is segmented –

1) By Product Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine

2) By Pathogen: Bacterial, Viral

3) By Disease Indication: Pneumococcal, Influenza, Meningococcal, Typhoid

4) By Patient: Pediatric, Adults

5) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users

Subsegments:

1) By Monovalent Conjugate Vaccines: Single Pathogen Conjugate Vaccines

2) By Multivalent Conjugate Vaccines: Multiple Pathogen Conjugate Vaccines, Combination Conjugate Vaccines

Which Regions Are Most Influential in Expanding the Conjugate Vaccine Market?

North America was the largest region in the global conjugate vaccine market in 2024. The regions covered in the conjugate vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Does the Definition of the Conjugate Vaccine Market Include?

Conjugate vaccines, also known as immunogen conjugates, are advanced immune system modulators widely employed to develop protection against invading pathogens or make particular antibodies against the target molecule. The conjugation process enhances the immune response and allows for a more effective immune system recognition of the pathogen.

Browse Through More Similar Reports By The Business Research Company:

Cancer Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

Dog Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/dog-vaccines-global-market-report

Veterinary Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/veterinary-vaccines-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: